H
Hans B. Lehmkuhl
Researcher at Humboldt University of Berlin
Publications - 206
Citations - 6748
Hans B. Lehmkuhl is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 40, co-authored 206 publications receiving 6281 citations. Previous affiliations of Hans B. Lehmkuhl include Charité.
Papers
More filters
Journal ArticleDOI
Noninvasive Diagnosis of Ischemia-Induced Wall Motion Abnormalities With the Use of High-Dose Dobutamine Stress MRI Comparison With Dobutamine Stress Echocardiography
Eike Nagel,Hans B. Lehmkuhl,Wolfgang Bocksch,Christoph Klein,Uta Vogel,E Frantz,Axel Ellmer,Stefan Dreysse,Eckart Fleck +8 more
TL;DR: High-doseDobutamine magnetic resonance tomography can be performed with a standard dobutamine/atropine stress protocol and yields a significantly higher diagnostic accuracy in comparison to DSE.
Journal ArticleDOI
Strain and Strain Rate Imaging by Echocardiography – Basic Concepts and Clinical Applicability
TL;DR: Strain and strain rate data provide valuable prognostic information, especially prediction of future reverse remodelling after left ventricular restoration surgery or after cardiac resynchronization therapy and prediction of short and median-term outcome without transplantation or ventricular assist device implantation of patients referred for heart transplantation.
Journal ArticleDOI
Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells
Torsten Bunde,Alexander Kirchner,Bodo Hoffmeister,Dirk Habedank,Roland Hetzer,Georgy Cherepnev,Susanna Proesch,Petra Reinke,Hans-Dieter Volk,Hans B. Lehmkuhl,Florian Kern +10 more
TL;DR: High frequencies of IE-1 but not pp65-specific CD8 T cells correlate with protection from CMV disease, which has important implications for monitoring T cell responses, adoptive cell therapy, and vaccine design.
Journal ArticleDOI
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Ulrich Trappe,Stephan Oertel,Véronique Leblond,Peter Mollee,Monica Sender,Petra Reinke,Ruth Neuhaus,Hans B. Lehmkuhl,Heinz A. Horst,Gilles Salles,Franck Morschhauser,Arnaud Jaccard,Thierry Lamy,Malte Leithäuser,Heiner Zimmermann,Ioannis Anagnostopoulos,Martine Raphael,Hanno Riess,Sylvain Choquet +18 more
TL;DR: The results support the use of sequential immunochemotherapy with rituximab and CHOP in PTLD and help to avoid the toxic effects of CHOP on patients with post-transplantation lymphoproliferative disorder.
Journal ArticleDOI
Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices.
Michael Dandel,Yuguo Weng,Henryk Siniawski,Evgenij V. Potapov,Hans B. Lehmkuhl,Roland Hetzer +5 more
TL;DR: For selected patients with IDCM, weaning from LVADs is a clinical option with good results over >9 years and should, therefore, be considered in those with cardiac recovery after LVAD implantation.